Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Lightweight Power, Unlimited Creativity: Canon Introduces the EOS R8 Mark II Full-Frame Camera and New Accessories

September 15, 2026

The EOS R8 Mark II is Canon’s lightest full-frame camera with stabilization

September 15, 2026

Defiance Launches AT, the First* U.S.-Listed ETF Dedicated to Robotics Actuators

September 15, 2026

MemeToro AI Agent Development Adds Fair-Launch Escrow and 1,373 Lines for Memecoin Investing

September 15, 2026

Nice Healthcare Supports Employers with Launch of New Health Plan

September 15, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Hepatology Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030
Press Release

Hepatology Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

By News RoomDecember 17, 20253 Mins Read
Hepatology Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Dec. 17, 2025 (GLOBE NEWSWIRE) — The “Hepatology Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030” has been added to ResearchAndMarkets.com’s offering.

The Global Hepatology Market, valued at USD 12.18 Billion in 2024, is projected to experience a CAGR of 8.60% to reach USD 19.98 Billion by 2030. The global hepatology market encompasses the study, prevention, diagnosis, and management of diseases affecting the liver, gallbladder, biliary tree, and pancreas, including conditions such as viral hepatitis, liver cirrhosis, fatty liver disease, and hepatocellular carcinoma. This market’s expansion is primarily driven by the escalating global prevalence of liver disorders, heightened public awareness regarding liver health, and continuous advancements in diagnostic methodologies.

Key Market Drivers: The increasing prevalence of liver diseases is a primary driver expanding the global hepatology market. Conditions like Non-Alcoholic Fatty Liver Disease are rising significantly, fueled by evolving dietary patterns and sedentary lifestyles. This widespread increase in patient populations directly generates greater demand for diagnostic tools, monitoring, and therapeutic interventions. According to “Worldwide burden of non-alcoholic fatty liver disease, 1990-2021: a systematic analysis of the Global Burden of Disease Study 2021” published on ResearchGate, in November 2024, an estimated 1.27 billion people were affected by NAFLD in 2021, highlighting this condition’s immense burden on global health systems.

Key Market Challenges: The high cost associated with advanced treatments presents a notable challenge for the global hepatology market. These substantial expenses frequently lead to restricted patient access, particularly in healthcare systems with stringent reimbursement policies or where individuals incur a significant proportion of out-of-pocket costs. The considerable financial strain placed on patients, healthcare providers, and payers can delay or prevent the widespread adoption of essential, innovative therapies, irrespective of their proven clinical efficacy. According to a 2024 study published in the Journal of Managed Care & Specialty Pharmacy, the mean annual healthcare costs per person were approximately $110,403 for patients diagnosed with cirrhosis, a severe liver condition, compared to $28,340 for those without cirrhosis.

Key Market Trends: Strategic Partnerships and Mergers for Pipeline Enhancement represent a crucial trend, as pharmaceutical and biotechnology companies seek to strengthen their portfolios and accelerate the development of novel liver disease treatments. These collaborations enable firms to share risks, leverage diverse expertise, and gain access to promising drug candidates, thereby expanding their market reach and competitive advantage. According to IQVIA, biopharma merger and acquisition activity in 2023 experienced a 79% increase in aggregate deal value compared to 2022, reaching approximately $152 billion, indicating robust investment in pipeline expansion across the biopharmaceutical sector.

Key Market Players Profiled:

  • Astellas Pharma Inc.
  • Merck & Co. Inc.
  • Abbott Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche AG
  • Eli Lilly and Company
  • Viatris Inc.
  • Gilead Sciences, Inc.

Report Scope: In this report, the Global Hepatology Market has been segmented into the following categories:

By Treatment Type:

  • Antiviral Drugs
  • Vaccines
  • Immunosuppressants
  • Targeted Therapy
  • Chemotherapy
  • Corticosteroids
  • Immunoglobulins

By Disease Type:

  • Hepatitis
  • Liver Cancer
  • Genetic Disorders
  • Autoimmune Diseases
  • Non-Alcoholic Fatty Liver Diseases
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Key Attributes:

Report Attribute Details
No. of Pages 183
Forecast Period 2024 – 2030
Estimated Market Value (USD) in 2024 $12.18 Billion
Forecasted Market Value (USD) by 2030 $19.98 Billion
Compound Annual Growth Rate 8.6%
Regions Covered Global

For more information about this report visit https://www.researchandmarkets.com/r/h63os1

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


            
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Lightweight Power, Unlimited Creativity: Canon Introduces the EOS R8 Mark II Full-Frame Camera and New Accessories

Defiance Launches AT, the First* U.S.-Listed ETF Dedicated to Robotics Actuators

MemeToro AI Agent Development Adds Fair-Launch Escrow and 1,373 Lines for Memecoin Investing

Nice Healthcare Supports Employers with Launch of New Health Plan

Beyond Meat® Announces Availability of Beyond Steak® Filet at Erewhon

Nearly All Fraudulent Hires Gain Active Corporate Credentials Before Detection, HYPR Research Finds

Magnitude Introduces CISO Staff Agent, an AI Chief of Staff for Third-Party Risk Management & Supply Chain Resilience

Food Lion Accelerates Growth with Six Additional New Store Openings in 2026 

New Report Finds 83% of Executives Say Their Job Security Depends on Scaling AI — Only 19% Have a Company-Wide Plan to Do It

Editors Picks

The EOS R8 Mark II is Canon’s lightest full-frame camera with stabilization

September 15, 2026

Defiance Launches AT, the First* U.S.-Listed ETF Dedicated to Robotics Actuators

September 15, 2026

MemeToro AI Agent Development Adds Fair-Launch Escrow and 1,373 Lines for Memecoin Investing

September 15, 2026

Nice Healthcare Supports Employers with Launch of New Health Plan

September 15, 2026

Latest News

Beyond Meat® Announces Availability of Beyond Steak® Filet at Erewhon

September 15, 2026

Nearly All Fraudulent Hires Gain Active Corporate Credentials Before Detection, HYPR Research Finds

September 15, 2026

Magnitude Introduces CISO Staff Agent, an AI Chief of Staff for Third-Party Risk Management & Supply Chain Resilience

September 15, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version